On Thursday, the FDA granted accelerated approval to Novartis AG’s (NYSE ... at risk of rapid disease progression. In ...
The US Food and Drug Administration has approved the use of Novartis' drug to reduce excess protein in the urine of patients with a type of kidney disease ... The FDA's latest approval was ...
Novartis NVS ... from the U.S. Food and Drug Administration for a treatment to bring down elevated levels of protein in the urine of adults who have a rare kidney disease. The approval follows ...
Novartis has secured US Food and Drug Administration (FDA) accelerated approval for Fabhalta (iptacopan) for reducing proteinuria in adults with primary IgA nephropathy (IgAN), a rare, progressive ...
The US FDA has approved a new orphan drug to treat patients with Cushing’s disease who cannot be helped through surgery. Novartis’ Signifor (pasireotide diaspartate) injection has been ...
Novartis’ $3.2 billion deal for Chinook Therapeutics gave the Swiss Big Pharma such a taste for kidney disease-focused ... iptacopan scored FDA approval in IgAN. That drug, marketed as Fabhalta ...
Reuters Health Information, August 07, 2024 US FDA Approves Novartis' Kidney Disease Drug The U.S. Food and Drug Administration has approved the use of Novartis' drug to reduce excess protein in ...
The FDA has approved Alnylam’s gene silencing drug ... As the kidney function worsens, oxalate can build up and damage other organs including the heart, bones and eyes. The disease is also ...
(FIle) The Food and Drug Administration on Monday approved Cara Therapeutics's drug to treat moderate-to-severe itching in patients with chronic kidney disease undergoing dialysis, making it the first ...
